Advertisement

Topics

Companies Related to "The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome" [Most Relevant Company Matches] RSS

16:57 EST 15th February 2019 | BioPortfolio

Here are the most relevant search results for "The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome" found in our extensive corporate database of over 50,000 company records.

Showing "Role Tumor Microenvironment Pancreatic Cancer Predict Treatment Outcome" Companies 1–25 of 5,400+

Extremely Relevant

World Pancreatic Cancer Coalition

The World Pancreatic Cancer Coalition is an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. Through global collaboration, the coalition raises awareness of pancreatic cancer by strengthening the efforts of participating member organizations. Each Novembe...


Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at the Barbara Ann Karmanos Cancer Institute to develop a diagnostic tool for the early detection of pancreatic cancer.

Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...


BioMarker Strategies

BioMarker Strategies (www.biomarkerstrategies.com) is a cancer diagnostics company that is developing a novel biomarker testing system to improve the treatment of cancer. SnapPath™ incorporates an automated and proprietary live-tumor-cell processing device with first-in-class, ex vivo biomarker tests to predict patient response to targeted cancer ther...

Quentis Therapeutics Inc.

Quentis Therapeutics is a preclinical stage biotechnology company that is pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer. Based on our deep expertise in ER stress biology and the tumor microenvironment, we are pioneering the use of ER stress response modulators to boost the i...

Quentis Therapeutics

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on our deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, we are pioneering first-in-class ER stress response modulators t...

KIYATEC, Inc.

KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated...

Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer within the general population, the medical community and the Government. We are developing educational programmes for trainee General Practitioners and are working on creating free Online Interactive...

Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization raises money for direct private funding of research -- and advocates for more aggressive federal research funding of medical breakthroughs in prevention, diagnosis and treatment of pancreatic canc...

OncoRx Pharmaceuticals Inc.

OncoRx Pharmaceuticals (www.oncorxpharmaceuticals.com) is an early-stage pharmaceutical company dedicated to the discovery and development of novel drugs that control tumor metastasis; disrupt proliferation; and downregulate tissue invasion of drug-resistant tumor cells. In the near term, the Company is planning clinical development programs for the treatm...

Relevant

Siamab Therapeutics, Inc.

Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class o...

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critical support in the search for better diagnostics and treatment of pancreatic cancer, and to date has provided more than $32 million to more than 115 research projects at 41 medical and research centers ...

OncoRx Pharmaceuticals, Inc.

OncoRx Pharmaceuticals (www.oncorxpharmaceuticals.com) is a pharmaceutical company dedicated to the discovery and development of novel drugs that control tumor metastasis; disrupt proliferation; disrupt sustained directional migration; and downregulate distant tissue invasion of drug-resistant tumor cells. In the near term, the Company is planning clinical...

Mitra Biotech Inc.

Mitra Biotech, with labs in India and the U.S., is engaged in enabling personalized cancer care and rational drug development through its proprietary pre-clinical platform called CANScriptTM. CANScriptTM is a multi-dimensional platform that can recreate the human tumor microenvironment while maintaining patient tumor heterogeneity, signaling networks and t...

Aravive Biologics, Inc.

Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer mali...

Partikula LLC

Partikula is a preclinical stage biotechnology company focused on developing novel therapies for cancer and other diseases based on platform chemistry technologies, including its first-in-class precision Tumor Microenvironment Modifiers (TMEM™), that are designed to deliver therapeutics to the mitochondria and other intracellular targets. Partikula wa...

Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the "Company") is a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading through...

Techniclone International Corporation

TECHNICLONE CORPORATION is engaged in the research and development of unique therapeutics for the treatment of cancer: The company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. The Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing minimal ...

X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer cells. The company’s oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in promoting the immunosuppressive and pro-angiogenic microenvironment...

Nanobiotix

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Nanobiotix is developing new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. Cancer is one of the leading causes of death worldwide and accounted for 7.6 million deaths (a...

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They a...

WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...


More From BioPortfolio on "The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks